Signed in as:
filler@godaddy.com
Suzhou Biomedical Industry Cluster
Temasek Biosparc (China-Singapore Life Science Park)
Suzhou Biomedical Industry Cluster
Over 4,200 biopharmaceutical enterprises, including 300+ MNCs - one of the largest and most internationally embedded biomedical clusters in China.
RMB 250 billion output value in 2025, accounting for ~6% of China‘s total.
The city is positioning itself as a globally top-tier biopharmaceutical innovation hub, not just a
manufacturing base.
Suzhou BioBAY (est. 2006)
Temasek Biosparc (China-Singapore Life Science Park)
Suzhou Biomedical Industry Cluster
Core carrier of SIP’s biomedical ecosystem hosting 630+ innovative biomedical enterprises.
National leader in talent and collaboration competitiveness.
Temasek Biosparc (China-Singapore Life Science Park)
Temasek Biosparc (China-Singapore Life Science Park)
Temasek Biosparc (China-Singapore Life Science Park)
Located on Suzhou Sangtian Science Island, the project focuses on gathering world-leading biopharmaceutical institutions and R&D innovation centers. Biosparc is currently under construction and expected to be opened in 2026. It will serve as the core carrier for China-Singapore biopharmaceutical cooperation. Total land area of 116,000 sqm
Located on Suzhou Sangtian Science Island, the project focuses on gathering world-leading biopharmaceutical institutions and R&D innovation centers. Biosparc is currently under construction and expected to be opened in 2026. It will serve as the core carrier for China-Singapore biopharmaceutical cooperation. Total land area of 116,000 sqm with an estimated total investment value of USD 148 million.
Biobay
By 2025, BioBAY accounts for:
- Over 20% of China’s innovative biomedical enterprises
- The largest concentration of top biomedical talent nationwide
- ~20% of China’s clinical approvals for Category I innovative biological drugs
- Significant shares of national production capacity and sector financing
The first National Technology Innovation Center for Biopharmaceuticals settled in 2021 in BioBay, focusing on nucleic acid drugs, cell therapy, gene therapy, and antibody drugs.
